Theseus Pharmaceuticals Ownership
Theseus Pharmaceuticals shows a total of 44.65 Million outstanding shares. The majority of Theseus Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Theseus Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Theseus Pharmaceuticals. Please pay attention to any change in the institutional holdings of Theseus Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Theseus Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Theseus Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Theseus |
Theseus Stock Ownership Analysis
About 93.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.81. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Theseus Pharmaceuticals has Price/Earnings (P/E) ratio of 737.67. The entity recorded a loss per share of 1.34. The firm last dividend was issued on the September 8, 2015. Theseus Pharmaceuticals had 1241:1000 split on the June 3, 2014. Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Theseus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. To find out more about Theseus Pharmaceuticals contact Timothy Clackson at 857 400 9491 or learn more at https://theseusrx.com.Theseus Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Theseus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Theseus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Theseus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
William Shakespeare over a year ago Exercise or conversion by William Shakespeare of 251084 shares of Theseus Pharmaceuticals subject to Rule 16b-3 | ||
Foresite Capital Management V Llc over a year ago Purchase by Foresite Capital Management V Llc of 176550 shares of Theseus Pharmaceuticals | ||
Dukes Iain D over a year ago Acquisition by Dukes Iain D of 3250 shares of Theseus Pharmaceuticals subject to Rule 16b-3 | ||
Kerstein David over a year ago Acquisition by Kerstein David of 17500 shares of Theseus Pharmaceuticals subject to Rule 16b-3 | ||
Kerstein David over a year ago Acquisition by Kerstein David of 105000 shares of Theseus Pharmaceuticals subject to Rule 16b-3 |
Theseus Pharmaceuticals Outstanding Bonds
Theseus Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Theseus Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Theseus bonds can be classified according to their maturity, which is the date when Theseus Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Theseus Stock
If you are still planning to invest in Theseus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Theseus Pharmaceuticals' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance |